You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Nitric Oxide Microfluidic Sensor

    SBC: CLINICAL SENSORS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant This Small Business Innovation Research SBIR Phase I project aims to develop a microfluidic based nitric oxide NO sensor as an early sepsis risk assessment device Sepsis causes significant strain on the U S healthcare system consuming over $ billion annually due to extended hospital stays and significant morbidity and mortality Rapid diagnosis and in ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. New small molecule inhibitors of arenaviruses

    SBC: MICROBIOTIX, INC.            Topic: R

    DESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenavirus ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. New heterocyclic inhibitors of filoviruses

    SBC: MICROBIOTIX, INC.            Topic: H

    DESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Picture Me Fit: Engaging Youth in Community-Based Prevention

    SBC: PREVENTION STRATEGIES, LLC            Topic: 600

    DESCRIPTION provided by applicant Approximately one third of all U S adults and children are obese and at risk for a wide range of related chronic health conditions such as cardiovascular disease hypertension diabetes stroke osteoarthritis sleep apnea and certain types of cancer The Center for Disease Control and Prevention CDC and other expert resources recognize that although indivi ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. A Pb-212 Generator Using Resistant Substrate and Rn Cold Trapping

    SBC: ALPHAMED, INC            Topic: N/A

    DESCRIPTION (provided by applicant): Targeted Pb-212 therapy in preclinical animal tests has shown a cure in groups receiving the highest dose of this therapy. Scaling the dose that was most efficacious in animal studies to people would bring the human dose required from 50 to 100 mCi. This application will research an approach that would provide a generator system that would support these require ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  6. Tribosupplementation of Injured Joints

    SBC: TRIBOLOGICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Injury is a well established risk factor in the pathogenesis of osteoarthritis (OA) as supported by several large longitudinal population studies. Patients with meniscal and ACL injuries in particular are at risk for early OA. Chondroprotection of the joint surface is mediated by lubricin which forms an ordered nanofilm and provides anti-adhesion via steric rep ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  7. An Acoustic Mobility Aid for the Visually Impaired

    SBC: BIOMIMETIC SYSTEMS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of this project is to develop a sonar system that can be used as a mobility aid by the visually impaired. The system will consist of an ultrasonic acoustic source using a waveform that is designed to optimize target discrimination and a pair of miniature microphones that are mounted near the ears to create natural interaural level and timing difference ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  8. A Nanofibrous Bioactive Prosthetic Sewing Cuff

    SBC: BIOSURFACES INC            Topic: N/A

    DESCRIPTION (provided by applicant): Cardiac valve replacement using prosthetic valves is indicated when progression of degenerative disease or bacterial infection of the native valve results in valvular dysfunction, thereby impacting on cardiac output. An estimated 50,000 prosthetic valves are implanted annually in the United States, with this number increasing due to an aging population and, to ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  9. Functional Tissue Engineering for Cartilage Repair

    SBC: Cytex Therapeutics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Degenerative joint diseases such as osteoarthritis remain the source of significant pain and disability, affecting 20 million adults with an economic burden of over 40 billion per year to the United States. While joint replacement is a well-established procedure, its finite life span makes this treatment unacceptable for younger or more active individuals, of ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  10. Development of ADAM10 Prodomain as a Therapeutic Agent

    SBC: BIOZYME, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Recent cancer therapies have focused on using biologics to target specific signal transduction pathways implicated in the tumor development or progression. For example, recombinant fusion proteins consisting of the extracellular domain of the immunoregluatory proteins and the constant (Fc) domain of immunoglobulin (IgG) represent a growing class of protein ther ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government